Development of Response Surface Pathway Design (RSP) in Laboratory Animals


> Professor Stig Larsen Norwegian University of Life Sciences Faculty of Veterinary Medicine and Biosciences

The stochastic nature in biology


This is not commonly taken into account in the planning phase of clinical trials.
Everything has to be strictly planned and stated in the trial protocol before start of the study.

 Whatever to be observed during the study, the protocol procedures is mainly to be kept unchanged.

Selection of LD50-doses



Selection of LD50-doses



Dose design in Laboratory Animal studies


- **Classic LD**₅₀ **design:** Trevan 1927; still in used today.
- **Up-and- Down design :** Dixon and Mood 1948; most commonly in use from 1960th.
- **Up-and-Down Procedure (UPD)**: Bruce 1985; standard method and recommended by OECD from 2002
- Random Walk design (RW): Tsutakawa 1967; Block UPD method and included in OECD
- 3+3 or A+B- design: Storer 1989 and Lin 2001; commonly in use from 2007
- Basic Response Surface Pathway design (RSP): Aune and Larsen 2007

Type of Designs in Dose-finding studies

Rule based design Classic LD50 , UPD, RW, 3+3, RSP


Statistical based designBayesian

A general four level Response Surface Pathway Design



Materials & Methods

- Priory knowledge: The LD₅₀ Yessotoxin window is 100-700 µg/kg. bw.
- Mouse strain: Male ICR
- Weight: 19-22.5g
- Number of dose levels: 4
- Starting dose in the response surface design: 400 µg/ kg. bw.



K-Adjustment factor


 $m_i = m_{i-1} \pm \frac{m}{2^{i-1}}$

 $m_i = m_{i-1} \pm \frac{m}{k^{i-1}}$

Calculation of K-Factor


Upper maximum dose = $D_U = m + m/k + m/k^2 + m/k^4 + m/k^8 = 700$

Lower minimum dose = $D_L = m - m/k - m/k^2 - m/k^4 - m/k^8 = 100$




From Binomial to multinomial outcome to determine dose levels

Nu	umber dead	Level 2 (m ₂)	Level 3 (m ₃)	Level 4 (m ₄)	Level 5 (m ₅)
0		m _{1 +} m ₁ /k	$m_{2+}m_1/k^2$	$m_{3+}m_1/k^3$	m ₄₊ m ₁ /k ⁴
1		$m_{1+}m_{1}/k^{2}$	$m_{2+}m_1/k^3$	$m_{3+}m_1/k^4$	m _{4 +} m ₁ /k ⁵
2		$m_{1} m_{1}/k^{2}$	$m_{2+}m_1/k^4$	$m_{3+}m_1/k^5$	m _{4 +} m ₁ /k ⁶
3		m ₁ m ₁ /k	$m_{2} m_{1}/k^{4}$	m _{3 +} m ₁ /k ⁶	$m_{4+}m_1/k^7$
4			$m_{2} m_{1}/k^{3}$	m ₃ _m₁/k⁵	$m_{4+}m_1/k^8$
5			$m_{2} m_{1}/k^{2}$	m ₃ m ₁ /k ⁵	m _{4 -} m ₁ /k ⁸
6				$m_{3-} m_1/k^4$	m _{4 -} m ₁ /k ⁷
7				m _{3 -} m ₁ /k ³	m _{4 -} m ₁ /k ⁵
8					m _{4 -} m ₁ /k ⁵
9					m ₄₋ m ₁ /k ⁴



Estimation of LD₅₀ of AZA1

- The dose window for AZA1in mouse is 25-375 µg/kg. bw.
- Mouse strain to be used : Female NMRI mice
- Mouse weight: 15 21 g
- Number of design-levels : 4
- Number of mice on design is 3, 5, 7 and 9
- Start dose in the RSP-design is chosen to $(375+25)/2 = 200 \ \mu g/kg$. bw.
- The dose adjustment k-factor calculated to k=2





Accuracy and needed sample size in estimation of LD₅₀ using basic- and developed RSP.

	Design	Dose (µg/kg BW)	Proportion of dead mice	LD ₅₀ with 95% CI (µg/kg BW)	No of mice needed
Service and	Basic RSP	400 450 500 600	3/9 4/9 7/9 5/9	463 (383 – 535) [152]	N=36
	*) Optimising use of mice	400 462 499 581	1/3 5/9 5/7 4/5	447 (378 – 504) [126]	N=24 {n=16}
	*) Multinomial decision variable with all four levels	400 465 468 482	1/3 3/7 4/9 3/5	473 (442 – 517) [75]	N=15 {n=9}